<DOC>
	<DOCNO>NCT00587119</DOCNO>
	<brief_summary>The purpose study find effect Budesonide , 9 mg daily one year , patient Primary Biliary Cirrhosis feature autoimmune hepatitis .</brief_summary>
	<brief_title>Oral Budesonide Treatment Patients With Primary Biliary Cirrhosis Overlap Features Autoimmune Hepatitis</brief_title>
	<detailed_description>Pilot Study Budesonide Primary Biliary Cirrhosis overlap feature Autoimmune Hepatitis Primary biliary cirrhosis ( PBC ) chronic liver disease unknown cause may result inflammation destruction bile duct inside liver . Over time , cirrhosis complication liver failure may develop . Although treatment ursodiol association reduction liver enzyme ( blood test ) reduction progression disease , patient respond ursodiol therapy . Patients overlap feature Autoimmune Hepatitis ( AIH ) appear high risk develop complication disease even ursodiol . The purpose study evaluate effect safety Budesonide PBC overlap feature AIH . Budesonide unique effect immune system may helpful treatment disease . Eligible participant include patient diagnosis PBC overlap feature AIH liver enzymes sufficiently improve ursodiol therapy ( alkaline phosphatase less twice upper normal ) . At entry patient history physical examination , blood test , bone densitometry complete quality life questionnaire . Patients prescribe Budesonide 9 mg take daily one year addition ursodiol . The medication take without food . Blood test symptoms diary complete every 3 month . Patients contact phone ass tolerance medication new health problem . At one year , patient return history physical repeat blood test bone densitometry . Possible side-effects include bone mass loss ( bone thinning ) , diarrhea , indigestion , nausea , joint pain , dizziness , headache , weight gain Cushing 's syndrome . Other side-effects possible . The medication test bill patient patient 's insurance .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Hepatitis , Autoimmune</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Chronic cholestatic liver disease great 6 month alkaline phosphatase level great 2 time upper limit normal . Positive AMA titer 1:40 AMA &gt; 1.0 U. Liver histology past ( available review ) feature consistent diagnostic PBC Ultrasound , compute tomography ( CT ) , cholangiography biliary tree excludes biliary obstruction . The diagnosis AIH necessary evaluation PBCAIH overlap syndrome base revised International Autoimmune Hepatitis Group ( IAHG ) Scoring System . Patients serious coexistent condition preexist advanced malignancy severe cardiopulmonary disease would expect limit expectancy less three year . Patients unable provide inform consent . Treatment methotrexate , corticosteroid , azathioprine , chlorambucil , cyclosporin , penicillamine , colchicine chenodeoxycholic acid precede three month . Anticipated need transplantation one year ( Mayo survival model &lt; 80 % oneyear survival without transplant ) . Liver biopsy reveal stage IV disease . Evidence portal hypertension esophageal varix , portal gastropathy , ascites hepatic encephalopathy . Known history portal vein thrombosis . Evidence osteoporosis . Serum bilirubin &gt; 4 mg/dl . Age le 21 year age great 75 year age . Pregnancy . Breastfeeding . Active drug alcohol use . Findings highly suggestive liver disease etiology chronic alcoholic liver disease , chronic hepatitis B C infection , hemochromatosis , Wilson 's disease , 1antitrypsin deficiency , nonalcoholic steatohepatitis sclerosing cholangitis . Serum creatinine 2.0 mg/dl . History document active peptic ulcer disease precede year .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Urso</keyword>
	<keyword>Budesonide</keyword>
	<keyword>PBC</keyword>
	<keyword>overlap AIH</keyword>
	<keyword>PBC overlap feature autoimmune hepatitis</keyword>
</DOC>